Vaccines against cholera, typhoid fever and shigellosis for developing countries (Q39217803)

10 September 2017

title

Vaccines against cholera, typhoid fever and shigellosis for developing countries (English)

1 reference

10 September 2017

0 references

1 reference

1 reference

C J Acosta

1 reference

10 September 2017

C M Galindo

1 reference

10 September 2017

J L Deen

1 reference

10 September 2017

R L Ochiai

1 reference

10 September 2017

H J Lee

1 reference

10 September 2017

L von Seidlein

1 reference

10 September 2017

R Carbis

1 reference

10 September 2017

J D Clemens

1 reference

10 September 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

Expert Opinion on Biological Therapy

10 September 2017

published in

1 reference

10 September 2017

1 reference

10 September 2017

1 reference

10 September 2017

page(s)

1939-1951

1 reference

Immunity of cholera in man: Relative role of antibacterial versus antitoxic immunity

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Field trial of a locally produced, killed, oral cholera vaccine in Vietnam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Construction and characterization of a nonproliferative El Tor cholera vaccine candidate derived from strain 638.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Typhoid fever in children aged less than 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Typhoid fever in Bangladesh: implications for vaccination policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

The emergence of multidrug resistance to antimicrobial agents for the treatment of typhoid fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Viet Nam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Salmonella typhi, the causative agent of typhoid fever, is approximately 50,000 years old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Protective activity of Vi capsular polysaccharide vaccine against typhoid fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

The mucosal immune system: from fundamental concepts to vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Isolation and Characterization of Gal E Mutant Ty 21a of Salmonella typhi: A Candidate Strain for a Live, Oral Typhoid Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Host-Salmonella interaction: human trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Persistent Efficacy of Vi Conjugate Vaccine against Typhoid Fever in Young Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Death in shigellosis: incidence and risk factors in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Phenotypic and genotypic characterization of provisional serotype Shigella flexneri 1c and clonal relationships with 1a and 1b strains isolated in Bangladesh

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

From virus to vaccine: developments using the simple eukaryote, Dictyostelium discoideum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Effective stimulation of the mucosal immune response by parenteral vaccination with weak antigen associated with a nucleoprotein vehicle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1939

10.1517/14712598.4.12.1939

21 January 2018

Identifiers

DOI

1 reference

10 September 2017

1 reference